NVP AAK 980
Alternative Names: NVP-AAK-980Latest Information Update: 11 Mar 2003
At a glance
- Originator Novartis
- Class Osteoporosis therapies; Small molecules
- Mechanism of Action Protein tyrosine kinase inhibitors; Src-family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Postmenopausal osteoporosis
Most Recent Events
- 11 Mar 2003 No development reported - Preclinical for Postmenopausal osteoporosis in Switzerland (unspecified route)
- 17 Jan 2000 Preclinical development for Postmenopausal osteoporosis in Switzerland (Unknown route)